New antibody infusion AM-928 enters early human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new drug called AM-928, given as an IV infusion, in about 38 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look for earl…
Phase: PHASE1 • Sponsor: AcadeMab Biomedical Inc. • Aim: Disease control
Last updated May 03, 2026 22:20 UTC